Details

Autor(en) / Beteiligte

• Cheng, Daryl R
• Clothier, Hazel J
• Morgan, Hannah J
• Roney, Emma
• Shenton, Priya
• Cox, Nicholas
• Jones, Bryn O
• Schrader, Silja
• Crawford, Nigel W
• Buttery, Jim P
• Goldsmith, Greta
• Hikmat, Samar
• Osowicki, Josh
• Phuong, Linny
• Addison, Mel
• Dempsey, Louise
• Harris, Adele
• Lewis, Georgie
• Penak, Bianca
• Voss, Laura
• Craft, Jaimee
• Scott, Victoria
• Tham, Lois
• Power, Anna
• Blow, Ngaree
• Sawmy, Elise Virah
• Duckworth, Eleanor
• Wolthuizen, Michelle
• Tenneti, Naveen
• White, Nick
• Heland, Melodie
• Gordon, Sally
• Standish, Jane
• McCloskey, Kathleen
• Doherty, Brooke
• Fleming, Catie
• Carr, Jeremy
• O’Brien, Matthew
• Loke, Paxton
• Earley, Ciara
• Tran, David
• O’Dea, Shane
• Cox, Lianne
• Asakawa, Yoko
• Lazzaro, Teresa
• Perrett, Kirsten
• Tosif, Shidan
• Uahwatanasakul, Wonie

Titel

Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12–17-year olds in Victoria, Australia

Ist Teil von

• BMJ paediatrics open, 2022-06, Vol.6 (1), p.e001472

Ort / Verlag

England: BMJ Publishing Group Ltd

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• ImportanceCOVID-19 mRNA vaccine-associated myocarditis has previously been described; however specific features in the adolescent population are currently not well understood.ObjectiveTo describe myocarditis adverse events following immunisation reported following any COVID-19 mRNA vaccines in the adolescent population in Victoria, Australia.DesignStatewide, population-based study.SettingSurveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) is the vaccine-safety service for Victoria, Australia.ParticipantsAll SAEFVIC reports of myocarditis and myopericarditis in 12–17-year-old COVID-19 mRNA vaccinees submitted between 22 February 2021 and 22 February 2022, as well as accompanying diagnostic investigation results where available, were assessed using Brighton Collaboration criteria for diagnostic certainty.ExposuresAny mRNA COVID-19 vaccine.Main outcomes/MmeasureConfirmed myocarditis as per Brighton Collaboration criteria (levels 1–3).ResultsClinical review demonstrated definitive (Brighton level 1) or probable (level 2) diagnoses in 75 cases. Confirmed myocarditis reporting rates were 8.3 per 100 000 doses in this age group. Cases were predominantly male (n=62, 82.7%) and post dose 2 (n=61, 81.3%). Rates peaked in the 16–17-year-old age group and were higher in males than females (17.7 vs 3.9 per 100 000, p=<0.001).The most common presenting symptoms were chest pain, dyspnoea and palpitations. A large majority of cases who had a cardiac MRI had abnormalities (n=33, 91.7%). Females were more likely to have ongoing clinical symptoms at 1-month follow-up (p=0.02).ConclusionAccurate evaluation and confirmation of episodes of COVID-19 mRNA vaccine-associated myocarditis enabled understanding of clinical phenotypes in the adolescent age group. Any potential vaccination and safety surveillance policies needs to consider age and gender differences.